Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs

Objective: The prevalence of breast cancer and gynaecological cancers is high, and these cancer types can occur consecutively as secondary cancers. The aim of our study is to determine the genes commonly expressed in these cancers and to identify the common hub genes and drug components. Materials...

Full description

Saved in:
Bibliographic Details
Main Author: Gizem Ayna Duran
Format: Article
Language:English
Published: Galenos Publishing House 2025-01-01
Series:European Journal of Breast Health
Subjects:
Online Access:https://www.eurjbreasthealth.com/articles/bioinformatics-based-drug-repurposing-approach-for-breast-and-gynecological-cancers-lessemgreaterrecql4fam13c-lessemgreatergenes-address-common-hub-genes-and-drugs/doi/ejbh.galenos.2024.2024-11-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841556256049856512
author Gizem Ayna Duran
author_facet Gizem Ayna Duran
author_sort Gizem Ayna Duran
collection DOAJ
description Objective: The prevalence of breast cancer and gynaecological cancers is high, and these cancer types can occur consecutively as secondary cancers. The aim of our study is to determine the genes commonly expressed in these cancers and to identify the common hub genes and drug components. Materials and Methods: Gene intensity values of breast cancer, gynaecological cancers such as cervical, ovarian and endometrial cancers were used from the Gene Expression Omnibus database Affymetrix Human Genome U133 Plus 2.0 Array project. Using the linear modelling method included in the R LIMMA package, genes that differ between healthy individuals and cancer patients were identified. Hub genes were determined using cytoHubba in Cytoscape program. “ShinyGo 0.80” tool was used to determine the disease-specific biological KEGG pathways. Drug.MATADOR from the ShinyGo 0.80 tool was used to predict drug-target relationships. Results: The RecQ Like Helicase 4 and Family with Sequence Similarity 13 Member C genes were found to be similarly expressed in breast cancer and gynaecological cancers. Upon KEGG pathway analyses with hub genes, Drug.MATADOR analysis with hub genes related to cancer related pathways was performed. We have determined these gene/drug interactions: NBN (targeted by Hydroxyurea), EP300 (targeted by Acetylcarnitine) and MAPK14 (targeted by Salicylate and Dibutyryl cyclic AMP). Conclusion: The drugs associated with hub genes determined in our study are not routinely used in cancer treatment. Our study offers the opportunity to identify the target genes of drugs used in breast and gynaecological cancers with the drug repurposing approach.
format Article
id doaj-art-07b41f2032a246c88c6ca4ae0a70401d
institution Kabale University
issn 2587-0831
language English
publishDate 2025-01-01
publisher Galenos Publishing House
record_format Article
series European Journal of Breast Health
spelling doaj-art-07b41f2032a246c88c6ca4ae0a70401d2025-01-07T11:01:29ZengGalenos Publishing HouseEuropean Journal of Breast Health2587-08312025-01-01211637310.4274/ejbh.galenos.2024.2024-11-2Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and DrugsGizem Ayna Duran0https://orcid.org/0000-0002-2168-753XDepartment of Biomedical Engineering Faculty of Engineering, İzmir University of Economics, İzmir, TurkeyObjective: The prevalence of breast cancer and gynaecological cancers is high, and these cancer types can occur consecutively as secondary cancers. The aim of our study is to determine the genes commonly expressed in these cancers and to identify the common hub genes and drug components. Materials and Methods: Gene intensity values of breast cancer, gynaecological cancers such as cervical, ovarian and endometrial cancers were used from the Gene Expression Omnibus database Affymetrix Human Genome U133 Plus 2.0 Array project. Using the linear modelling method included in the R LIMMA package, genes that differ between healthy individuals and cancer patients were identified. Hub genes were determined using cytoHubba in Cytoscape program. “ShinyGo 0.80” tool was used to determine the disease-specific biological KEGG pathways. Drug.MATADOR from the ShinyGo 0.80 tool was used to predict drug-target relationships. Results: The RecQ Like Helicase 4 and Family with Sequence Similarity 13 Member C genes were found to be similarly expressed in breast cancer and gynaecological cancers. Upon KEGG pathway analyses with hub genes, Drug.MATADOR analysis with hub genes related to cancer related pathways was performed. We have determined these gene/drug interactions: NBN (targeted by Hydroxyurea), EP300 (targeted by Acetylcarnitine) and MAPK14 (targeted by Salicylate and Dibutyryl cyclic AMP). Conclusion: The drugs associated with hub genes determined in our study are not routinely used in cancer treatment. Our study offers the opportunity to identify the target genes of drugs used in breast and gynaecological cancers with the drug repurposing approach.https://www.eurjbreasthealth.com/articles/bioinformatics-based-drug-repurposing-approach-for-breast-and-gynecological-cancers-lessemgreaterrecql4fam13c-lessemgreatergenes-address-common-hub-genes-and-drugs/doi/ejbh.galenos.2024.2024-11-2breast cancergynaecological cancersdegshub genesdrug repurposingrecql4/fam13c
spellingShingle Gizem Ayna Duran
Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs
European Journal of Breast Health
breast cancer
gynaecological cancers
degs
hub genes
drug repurposing
recql4/fam13c
title Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs
title_full Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs
title_fullStr Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs
title_full_unstemmed Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs
title_short Bioinformatics Based Drug Repurposing Approach for Breast and Gynecological Cancers: RECQL4/FAM13C Genes Address Common Hub Genes and Drugs
title_sort bioinformatics based drug repurposing approach for breast and gynecological cancers recql4 fam13c genes address common hub genes and drugs
topic breast cancer
gynaecological cancers
degs
hub genes
drug repurposing
recql4/fam13c
url https://www.eurjbreasthealth.com/articles/bioinformatics-based-drug-repurposing-approach-for-breast-and-gynecological-cancers-lessemgreaterrecql4fam13c-lessemgreatergenes-address-common-hub-genes-and-drugs/doi/ejbh.galenos.2024.2024-11-2
work_keys_str_mv AT gizemaynaduran bioinformaticsbaseddrugrepurposingapproachforbreastandgynecologicalcancersrecql4fam13cgenesaddresscommonhubgenesanddrugs